Novel Muscle Therapeutics Through Selective Beta-Adrenoceptor Signalling
Novel Muscle Therapeutics Through Selective Beta-Adrenoceptor Signalling
批准号:
nhmrc : 1026231
负责人:
A/Pr Paul Gregorevic
金额:
$40.25万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2012
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2012-01-01 至 2015-12-31
中文摘要
肌肉萎缩是一种紧迫且未得到满足的健康风险,通常与衰老、癌症、肌肉疾病以及包括心血管和代谢紊乱在内的疾病有关。操纵β-肾上腺素能信号传导是肌肉萎缩的治疗靶点,但由于心血管副作用,迄今为止治疗受到限制。使用尖端技术,我们将确定有效分离对骨骼肌有益影响和对心脏有害影响的治疗方法。
英文摘要
Muscle wasting is an urgent and unmet health risk commonly associated with ageing; cancer, muscle diseases, and conditions including cardiovascular and metabolic disorders. Manipulating beta-adrenergic signalling is a therapeutic target for muscle wasting but treatments have so far been limited due to cardiaovascular side effects. Using cutting edge technologies, we will identify treatments that effectively separate beneficial effects on skeletal muscles from unwanted effects on the heart.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rescuing the dystrophin-glycoprotein complex to protect muscles from wasting conditions
-
批准号:nhmrc : GNT1144772
-
项目类别:Project Grants
-
资助金额:$83.33万
-
财政年份:2018
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Rescuing the dystrophin-glycoprotein complex to protect muscles from wasting conditions
-
批准号:nhmrc : 1144772
-
项目类别:Project Grants
-
资助金额:$56.35万
-
财政年份:2018
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
The effects of ACTN3 R577X on muscle wasting and repair, and response to therapy
-
批准号:nhmrc : 1130215
-
项目类别:Project Grants
-
资助金额:$72.83万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Investigating follistatin-based interventions for long term-protection against frailty associated with chronic illness and aging
-
批准号:nhmrc : GNT1121500
-
项目类别:Project Grants
-
资助金额:$98.72万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Investigating follistatin-based interventions for long term-protection against frailty associated with chronic illness and aging
-
批准号:nhmrc : 1121500
-
项目类别:Project Grants
-
资助金额:$67.47万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
The effects of ACTN3 R577X on muscle wasting and repair, and response to therapy
-
批准号:nhmrc : GNT1130215
-
项目类别:Project Grants
-
资助金额:$106.61万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Using gene delivery technologies to define novel mechanisms of skeletal muscle adaptation, and develop muscle-directed interventions for frailty and serious illness
-
批准号:nhmrc : GNT1117835
-
项目类别:Research Fellowships
-
资助金额:$63.14万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Using gene delivery technologies to define novel mechanisms of skeletal muscle adaptation, and develop muscle-directed interventions for frailty and serious illness
-
批准号:nhmrc : 1117835
-
项目类别:Research Fellowships
-
资助金额:$43.17万
-
财政年份:2017
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Pre-clinical assessment of the therapeutic potential of targeting the Hippo pathway in muscle wasting & muscle-derived cancer
-
批准号:nhmrc : GNT1099588
-
项目类别:Project Grants
-
资助金额:$62.2万
-
财政年份:2016
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Pre-clinical assessment of the therapeutic potential of targeting the Hippo pathway in muscle wasting & muscle-derived cancer
-
批准号:nhmrc : 1099588
-
项目类别:Project Grants
-
资助金额:$42.65万
-
财政年份:2016
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Using gene delivery tools to understand and treat skeletal muscle-related disease
-
批准号:nhmrc : 1046782
-
项目类别:Career Development Fellowships
-
资助金额:$30.62万
-
财政年份:2013
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Investigating Hippo signalling as a novel cause of muscle disease, and as a target for new interventions to combat frailty
-
批准号:nhmrc : 1009995
-
项目类别:Project Grants
-
资助金额:$30.71万
-
财政年份:2011
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Defining mechanisms of follistatin-mediated muscle adaptation, for treatment of frailty and muscle-related diseases
-
批准号:nhmrc : 526648
-
项目类别:NHMRC Project Grants
-
资助金额:$37.17万
-
财政年份:2009
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
Targeting beta-adrenergic signalling to improve muscle regeneration in muscular dystrophy
-
批准号:nhmrc : 509313
-
项目类别:NHMRC Project Grants
-
资助金额:$31.55万
-
财政年份:2008
-
负责人:A/Pr Paul Gregorevic
-
依托单位:
海外基金